To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

November 11, 2024

Study Completion Date

March 18, 2025

Conditions
Dermatitis, Atopic
Interventions
DRUG

Placebo

Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 1

SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 2

SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 3

SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.

Trial Locations (58)

101

Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC, Tbilisi

112

Israeli - Georgian Medical Research Clinic Healthycore LLC, Tbilisi

144

Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC, Tbilisi

159

Emergency Cardiology Center by Academician G. Chapidze LLC, Tbilisi

160

LTD Aversi Clinic, Tbilisi

TIM - Tbilisi Institute of Medicine LLC, Tbilisi

179

David Abuladze Georgian-Italian Clinic LLC, Tbilisi

22209

Skin DC Derm, Arlington

30349

Oracle Clinical Research, College Park

32720

Accel Research Sites Network - Annexus Dermatology & Aestheitcs, DeLand

33012

Direct Helpers Research Center, Hialeah

Evolution Research Center, Hialeah

33016

Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research, Hialeah

Evolution Clinical Trials, Inc, Hialeah Gardens

33027

FXM Clinical Research Miramar, Miramar

33122

Revival Research Corporation, Doral

33135

Advanced Clinical Research Network, Corp, Miami

33145

MedOne Clinical Research, LLC, Miami

33173

Century Research LLC, Miami

33175

FXM Clinical Research Miami, Miami

33176

JD Medical Group, LLC, Miami

33308

FXM Clinical Research Fort Lauderdale, Fort Lauderdale

33607

Advanced Clinical Research Institute, Florida City

Adtremed Inc, Tampa

33615

Alliance Clinical Research of Tampa, Tampa

47906

Physicians Research Group, West Lafayette

48084

Revival research Institute, LLC, Troy

50106

Clinical Research Centre OU, Tartu

75149

SMS Clinical Research, Mesquite

75234

DFW Clinical Research, Dallas

77479

Stride Clinical Research, Sugar Land

79902

3A Research, El Paso

80109

Clarity Dermatology, Castle Rock

84663

Springville Dermatology/ CCT Research, Springville

85018

Omni Dermatology, Phoenix

85364

Yuma Clinical Trials, LLC, Yuma

90017

Metropolis Dermatology, Los Angeles

90036

Axis Clinical Trials, Los Angeles

91403

Unison Clinical Trials, Sherman Oaks

91436

T. Joseph Raoof Md, Imc./Encino Research Center, Encino

91606

Providence Clinical Research, North Hollywood

91790

Providere' Research Inc., West Covina

CP 01101

Clinica Vargas, San Salvador

CP 1101

Clinica Dermatologica, San Salvador

CP: 01501

Clinica de Dermatologia y Cirugia de Piel, Santa Tecla

15-704

KLIMED, Bialystok

80-382

Synexus Polska Sp. z o.o. Branch in Gdansk, Gdansk

31-011

Dobry Lekarz' Modern Therapies Center Limited Liability Company, Krakow

31-156

Landa Specialist Doctor's Offices, Krakow

57-300

GLOBE Clinical Research, Kłodzko

90-349

Appletreeclinics Clinical Research Centre, Lodz

20-607

Dermedic Iwona Zdybska, Lublin

60-309

"EMC Medical Institute Joint Stock Company, Certus Private Healthcare Facility Hospital No. 1", Poznan

71-500

TWOJA PRZYCHODNIA Medical Centre of Szczecin, Twoja Przychodnia SCM, Szczecin

02-507

National Medical Institute of the MSWiA, Clinical Department of Dermatology, Warsaw

02-672

Synexus Polska Sp. z o.o. Branch in Warsaw, Warsaw

04-141

Military Institute of Medicine - National Research Institute, Department of Dermatology CWBK, Warsaw

50-381

Synexus Polska Sp. z o.o. Branch in Wroclaw, Wroclaw

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT04684485 - To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter